Mayo Clinic and Alpenglow Biosciences have announced a collaboration to integrate Alpenglow's 3D spatial biology platform to accelerate drug development and advance clinical diagnostics for the clinic's patients.
According to a Cision PR Newswire, the company created an end-to-end 3D spatial biology solution that integrates exclusive high-throughput 3D imaging, cloud-based bioinformatics pipelines with GPU acceleration and spatial analysis driven by artificial intelligence.
"The future of pathology is digital and 3D, and we are excited to collaborate with Alpenglow to benefit researchers, external partners and, ultimately, patients," Dr. Bobbi Pritt, Chair of Mayo Clinic's Department of Laboratory Medicine and Pathology, told Cision PR Newswire.
"This collaboration aims to unlock additional insights and expand the offerings while driving innovation within our biopharma diagnostics space and the Advanced Diagnostics Laboratory," Dr. William Morice, president and CEO of Mayo Clinic Laboratories, told Cision PR Newswire.
Alpenglow's 3D spatial biology platform will be integrated with multi-omics approaches, including multiplex immunofluorescence and single-cell sequencing to predict response to therapy and patient prognosis using Mayo Clinic's unique biospecimen repositories.
According to the collaborative study, which was presented at the American Association for Cancer Research Annual Meeting 2023, Alpenglow's 3D spatial technology allows clinicians to skip the current, 2D slide analysis, instead going direct to digital with 3D imaging and AI-powered insights.
"Tissue contains incredible insights into disease processes and therapeutic mechanisms of action, but the problem is we miss 99% of that information with traditional slide-based pathology," said Dr. Nicholas Reder, cofounder of Alpenglow Biosciences, according to Cision PR Newswire.
Although pathology has seen significant advancements in recent years with the digitization of 2D slides, automated slide scanning and AI analysis, Alpenglow has built a "leapfrog technology," which allows them to cut out slides entirely.
"In collaboration with Mayo Clinic's deep clinical and pathology expertise, we're focused on solving the biggest problems facing pathology to accelerate drug development and advance clinical diagnostics," Reder told Cision PR Newswire.
